Investors & Media
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases.
- Today's Open
- Previous Close
- Today's High
- Today's Low
- 52 Week High
- 52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Mar 06, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 01, 2023 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- Feb 27, 2023 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
- Mar 13, 2023 3:20 PM EDT Oppenheimer’s 33rd Annual Healthcare Conference: Virtual fireside chat
- Mar 9, 2023 9:10 AM EST Cowen 43rd Annual Healthcare Conference: Fireside chat
- Feb 17, 2023 4:30 PM EST Apellis SYFOVRE FDA Approval Conference Call